Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipepidine for ADHD
NCT01835093Phase 2Completed
- Sponsor
- Chiba University
- Start
- Apr 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipepidine hibenzate in attention deficit hyperactivity disorder (ADHD), sponsored by Chiba University. Primary endpoint: ADHD Rating Scale-IV Japanese Version at 4 weeks. Started Apr 2013; status: completed.
02
Drugs
tipepidine hibenzate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01835093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835093.